FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Diamandis Peter		 2. Date of Event Requiring Statement (MM/DD/YYYY)
11/10/2021 

 3. Issuer Name and Ticker or Trading Symbol

Vaxxinity, Inc. [VAXX]
(Last)        (First)        (Middle)

1717 MAIN STREET, SUITE 3388		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

DALLAS, TX 75201      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
11/10/2021 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A preferred stock (1) (2) (2)Class A common stock 13824 (2) (2)D  
Explanation of Responses:
(1) The Reporting Person unintentionally omitted this holding from the Form 3 filed on November 10, 2021.
(2) The 21,511 shares of Series A preferred stock will convert into 13,824 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Diamandis Peter
1717 MAIN STREET
SUITE 3388
DALLAS, TX 75201		X
Signatures
/s/ Rene Paula Molina, attorney-in-fact for Peter Diamandis6/23/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vaxxinity Charts.
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vaxxinity Charts.